Home/ Stocks/ GILD

Gilead Sciences Inc

GILD XNAS

$138.11 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$170.50B

About Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 17.0K Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$29.44B	$8.51B	$6.84
FY 2025	$29.44B	$8.51B	$6.84
Q3 2025	$7.77B	$3.05B	$2.46
Q2 2025	$7.08B	$1.96B	$1.57

TickerDaily Coverage

Why Is Arcellx, Inc. Common Stock (ACLX) Stock Up 77.4% Today?

Market News Alex Chen · Feb 24, 2026

Arcellx stock exploded 77.4% to $113.75 on a massive 32.9M-share volume surge after Gilead Sciences...

Why Is Arcellx, Inc. Common Stock (ACLX) Stock Up 77.7% Today?

Market News Alex Chen · Feb 23, 2026

Arcellx stock exploded 77.7% today after Gilead Sciences announced it would acquire the...

View All Coverage →

Get GILD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Gilead Sciences Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.